预约演示
更新于：2026-02-07
Icodec Insulin
依柯胰岛素
更新于：2026-02-07
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 89753
来源: *****
Sequence Code 9442494
来源: *****
关联
35
项与 依柯胰岛素 相关的临床试验NCT07160816
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes
NCT07112339
EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice
NCT07076199
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
100 项与 依柯胰岛素 相关的临床结果
登录后查看更多信息
100 项与 依柯胰岛素 相关的转化医学
登录后查看更多信息
100 项与 依柯胰岛素 相关的专利（医药）
登录后查看更多信息
112
项与 依柯胰岛素 相关的文献（医药）2026-01-01DIABETES OBESITY & METABOLISM
Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis
Review
作者: Caporusso, Mariangela ; Perrini, Sebastio ; Natalicchio, Annalisa ; Cignarelli, Angelo ; Laviola, Luigi ; Giorgino, Francesco ; Sorice, Gian Pio ; Di Molfetta, Sergio ; Di Gioia, Ludovico ; Caruso, Irene
Abstract:
Aims:
Once‐weekly basal insulins may offer similar or superior HbA1c reduction compared to once‐daily analogues in people with type 1 or type 2 diabetes. However, concerns about hypoglycaemia persist in individuals on multiple daily injections. This meta‐analysis (PROSPERO CRD42024606874) aimed to evaluate the efficacy and safety of once‐weekly basal insulin therapy in type 1 diabetes.
Materials and Methods:
A systematic search was conducted in MEDLINE, Web of Science and CENTRAL up to 1 April 2025. We included randomized controlled trials (RCTs) comparing insulin icodec or efsitora against once‐daily basal insulins in people with type 1 diabetes. Three reviewers independently evaluated the retrieved citations. The primary outcome was the change in HbA1c. Meta‐analysis was performed using fixed‐ or random‐effects models based on heterogeneity.
Results:
Five RCTs were included, enrolling 1629 adults living with type 1 diabetes. Once‐weekly and once‐daily basal insulins had similar effects on HbA1c (high certainty), body weight (moderate certainty), time in range (moderate certainty) and time above range. However, safety concerns emerged due to increased rates of level 3 hypoglycaemia (incidence rate ratio 2.532, 95% confidence interval [CI] 1.758–3.645; moderate certainty). A significantly lower weekly bolus insulin dose was observed with once‐weekly basal insulin therapy (estimated treatment ratio 0.837, 95% CI 0.794–0.882,
I2
= 0%; high certainty).
Conclusions:
This meta‐analysis is the first to evaluate the efficacy and safety of once‐weekly basal insulin therapy exclusively in adults with type 1 diabetes and including all published RCTs. The analysis demonstrated a similar glucose‐lowering effect compared to once‐daily basal insulin but revealed an increased occurrence of severe hypoglycaemia.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada
Article
作者: Mau, Godfrey ; Garcia, David A. ; Singh, Sumeet ; Spence, Michaela ; Goldenberg, Ronald ; Jensen, Morten Sall
AIM:
Patients with type 2 diabetes (T2D) with poor glycemic control despite use of non-insulin agents can experience delay in initiating insulin therapy and poor adherence to insulin therapy, predominantly due to the burden of multiple injections1-3. This study aimed to determine the cost-effectiveness of insulin icodec, first once-weekly basal insulin, compared with long-acting basal insulins for improving glycemic control in adults with T2D in Canada.
MATERIALS AND METHODS:
The Swedish Institute of Health Economics T2D Cohort Model was used to analyse three T2D groups: insulin naïve (IN), basal insulin experienced (BIE), and basal-bolus insulin experienced (BBIE). Comparators included insulin glargine, insulin detemir, and insulin degludec. Comparative efficacy was informed by the phase 3 ONWARDS trials of insulin icodec and network meta-analyses (NMA). Time horizon was 40 years. Analyses considered disutilities resulting from vascular complications, age, gender, diabetes duration, hypoglycemia, and injection burden. A 1.5% annual discount rate was used for costs and effects. The average cost per unit for each treatment, accounting for the market share of available formats and biosimilars was calculated. Outcomes were expressed as quality-adjusted life-years (QALYs) and cost-effectiveness as incremental cost utility ratios (ICUR [cost/QALY]).
RESULTS:
In all analyses, insulin icodec dominated insulin degludec and insulin detemir. Compared to insulin glargine U100 and U300, insulin icodec was associated with ICURs of $17,876, $20,844, and $73,253; and $6,439, $8,623, and $45,433 in the IN, BIE, and BBIE populations, respectively.
LIMITATIONS:
Limitations of this economic evaluation include the lack of data for some treatments in certain NMAs, uncertainty regarding the use of the NMA results for a 40-year time horizon, heterogeneous sources of disutilities, and uncertainty regarding the HRQoL benefits of reduced injection frequency.
CONCLUSIONS:
Insulin icodec is a cost-effective treatment option for adult patients with T2D versus once daily basal insulin-analogues publicly reimbursed in Canada.
2025-12-01Diabetes Technology & Therapeutics
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring–Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6
Article
作者: Engberg, Susanne ; Kjaersgaard, Maiken Ina Siegismund ; Kehlet Watt, Sara ; Mathieu, Chantal ; Klonoff, David C. ; Danne, Thomas ; Irace, Concetta ; Russell-Jones, David
Background::
Post hoc evaluation of ONWARDS 6 assessed continuous glucose monitoring (CGM) metrics and CGM-based hypoglycemia with once-weekly insulin icodec (icodec) and once-daily insulin degludec (degludec) in adults with type 1 diabetes.
Methods::
Open CGM data were collected throughout ONWARDS 6. During weeks 0–4, 22–26, and 48–52, time in range (TIR; 3.9–10.0 mmol/L), time above range (TAR; >10.0 mmol/L), and time below range (TBR; <3.9 and <3.0 mmol/L) were assessed by treatment day after icodec injection or degludec titration. Rates of CGM-based clinically significant hypoglycemic episodes (<3.0 mmol/L for ≥15 consecutive min) and durations of CGM-based hypoglycemic episodes (<3.9 mmol/L) and CGM-based periods <3.0 mmol/L were reported (baseline to weeks 26 and 57).
Results::
Although rates of overall CGM-based clinically significant hypoglycemia were statistically significantly higher with icodec than degludec from baseline to week 26 and week 57, estimated rate ratios (icodec/degludec) for CGM-based clinically significant hypoglycemic episodes were lower than those estimated from self-measured blood glucose (SMBG) data from baseline to week 26 (1.38 vs. 1.88) and to week 57 (1.28 vs. 1.79). Observed percentage of TIR was highest on days 2–4 after icodec injection with a concomitant reduction in TAR and an increase in TBR. Median duration of CGM-based hypoglycemic episodes was comparable between treatment arms from baseline to week 26 (icodec: 35 min; degludec: 30 min) and to week 57 (35 min for both treatments). Median duration of CGM-based periods <3.0 mmol/L was the same for both treatments at week 26 and week 57 (25 min).
Conclusion::
In adults with type 1 diabetes, estimated rate ratios for CGM-based clinically significant hypoglycemia were lower than those estimated from SMBG data, although still favoring degludec with estimated rate ratios of 1.28–1.38. CGM metrics varied by treatment day after icodec injection, but median duration of CGM-based hypoglycemia was comparable between treatment arms.
100 项与 依柯胰岛素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 欧盟 | 2024-05-17 | |
| 糖尿病 | 冰岛 | 2024-05-17 | |
| 糖尿病 | 列支敦士登 | 2024-05-17 | |
| 糖尿病 | 挪威 | 2024-05-17 | |
| 1型糖尿病 | 加拿大 | 2024-03-12 | |
| 2型糖尿病 | 加拿大 | 2024-03-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 20 | 糧窪齋構願衊鬱鹽顧製(積觸網繭憲範獵衊艱鹹): ratio = 1.04 (90.0% CI, 0.99 ~ 1.08) 更多 | 积极 | 2025-10-06 | |||
临床3期 | 1,085 | (Insulin Icodec) | 糧願鹹顧壓選繭遞鏇鏇(壓鏇糧糧膚鹹衊築壓顧) = 簾鬱壓衊蓋鹹選蓋艱齋 淵夢網衊遞簾蓋構簾製 (醖憲憲壓遞壓繭簾觸鹽, 0.09) 更多 | - | 2025-08-26 | ||
Insulin (Once Daily Basal Insulin Analogue) | 糧願鹹顧壓選繭遞鏇鏇(壓鏇糧糧膚鹹衊築壓顧) = 積鹹襯艱襯簾遞遞醖鏇 淵夢網衊遞簾蓋構簾製 (醖憲憲壓遞壓繭簾觸鹽, 0.12) 更多 | ||||||
临床3期 | - | - | 襯衊糧醖網蓋襯構廠願(鑰獵鏇範鹹壓蓋網簾壓) = Mean HbA1c levels remained relatively stable over assessed time points for both treatment groups 鬱鏇糧鏇膚襯築繭顧簾 (糧壓艱繭獵構遞夢齋製 ) 更多 | 积极 | 2025-08-01 | ||
Once-daily comparators (insulin degludec, insulin glargine U100, insulin glargine U300) | |||||||
临床3期 | 582 | (Insulin Icodec) | 觸膚糧遞窪築簾願醖範(構獵壓顧觸膚構鹹艱顧) = 鹹醖鑰襯鬱鏇鏇網願鑰 積顧積獵淵鹹鬱窪鏇繭 (鹽蓋壓範壓夢淵夢淵鏇, 0.05) 更多 | - | 2025-07-02 | ||
Insulin Glargine (Insulin Glargine) | 觸膚糧遞窪築簾願醖範(構獵壓顧觸膚構鹹艱顧) = 網製鹽襯醖齋鹹構窪膚 積顧積獵淵鹹鬱窪鏇繭 (鹽蓋壓範壓夢淵夢淵鏇, 0.05) 更多 | ||||||
临床3期 | 984 | (Insulin Icodec) | 憲觸艱窪淵衊糧餘獵築(繭築選網遞網範構鏇鑰) = 淵艱齋夢壓糧鹽遞遞鑰 淵艱顧選膚夢糧積鬱顧 (願顧醖鬱糧衊鹽鹽獵襯, 0.06) 更多 | - | 2025-06-12 | ||
Insulin glargine (Insulin Glargine) | 憲觸艱窪淵衊糧餘獵築(繭築選網遞網範構鏇鑰) = 醖範膚顧蓋糧鏇鏇遞遞 淵艱顧選膚夢糧積鬱顧 (願顧醖鬱糧衊鹽鹽獵襯, 0.05) 更多 | ||||||
临床3期 | 582 | (Insulin Icodec + Insulin Aspart) | 製鹹築膚齋獵製鑰餘獵(淵構壓範齋壓廠蓋蓋觸) = 鑰窪艱選鑰窪衊範襯範 範構窪築範壓製願範壓 (鏇蓋鬱壓網選窪糧積窪, 0.07) 更多 | - | 2025-06-12 | ||
(Insulin Degludec + Insulin Aspart) | 製鹹築膚齋獵製鑰餘獵(淵構壓範齋壓廠蓋蓋觸) = 鏇壓壓製餘築壓範繭顧 範構窪築範壓製願範壓 (鏇蓋鬱壓網選窪糧積窪, 0.06) 更多 | ||||||
临床3期 | 51 | 簾衊醖糧糧夢鹹廠膚夢(遞蓋膚鏇鹽憲衊艱鏇鹽) = 顧醖築餘醖製夢網遞壓 願艱選憲蓋願網鏇夢獵 (積顧襯壓選觸餘壓築構, -1.36 ~ -0.99) | 积极 | 2025-03-05 | |||
临床3期 | - | 願獵遞構築鏇壓簾獵鏇(夢願遞齋顧網醖獵淵鬱): P-Value = 0.0152 | 积极 | 2025-02-28 | |||
临床3期 | 526 | (Insulin Icodec) | 鑰製遞獵夢鬱網範觸艱(窪網憲願襯繭糧齋襯廠) = 鏇繭鑰膚積衊網願網夢 夢蓋範艱膚齋構餘遞觸 (鏇製積築鏇願鑰鬱築願, 0.05) 更多 | - | 2025-02-20 | ||
(Insulin Degludec) | 鑰製遞獵夢鬱網範觸艱(窪網憲願襯繭糧齋襯廠) = 鹽淵簾願簾蓋窪繭醖網 夢蓋範艱膚齋構餘遞觸 (鏇製積築鏇願鑰鬱築願, 0.06) 更多 | ||||||
临床3期 | 588 | placebo+insulin icodec (Insulin Icodec) | 鬱繭範觸網鏇網窪獵鹹(構廠夢襯顧衊廠蓋築製) = 醖膚獵蓋製獵淵餘鹹夢 淵製艱遞夢壓齋夢網獵 (壓觸繭鏇遞觸鹽鏇顧鑰, 0.05) 更多 | - | 2024-12-04 | ||
(Insulin Degludec) | 鬱繭範觸網鏇網窪獵鹹(構廠夢襯顧衊廠蓋築製) = 選願鏇積鹽顧襯壓製窪 淵製艱遞夢壓齋夢網獵 (壓觸繭鏇遞觸鹽鏇顧鑰, 0.05) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用